Indonesia Early Toxicity Testing Market

1      INTRODUCTION

           1.1      REPORT DESCRIPTION

           1.2      RESEARCH METHODOLOGY

                         1.2.1      SECONDARY RESEARCH

                         1.2.2      DATA ANALYSIS FRAMEWORK

                         1.2.3      MARKET SIZE ESTIMATION

                         1.2.4      FORECASTING

                         1.2.5      PRIMARY RESEARCH AND DATA VALIDATION

2      INDONESIA EARLY TOXICITY TESTING MARKET – EXECUTIVE SUMMARY

           2.1.      MARKET SNAPSHOT, 2022 - 2030, Million USD

3      PORTER’S FIVE FORCE MODEL ANALYSIS

           3.1      BARGAINING POWER OF SUPPLIERS

           3.2      BARGAINING POWER OF BUYERS

           3.3      DEGREE OF COMPETITION

           3.4      THREAT OF SUBSTITUTE

           3.5      THREAT OF NEW ENTRANTS

4      MARKET SHARE ANALYSIS

           4.1      MARKET SHARE ANALYSIS OF TOP PROVIDERS, 2022

5      MARKET DYNAMICS

           5.1      GROWTH DRIVERS

                         5.1.1      Increasing Foreign Investment Fuels Market Growth

                         5.1.2      Rising Government Promotion of Traditional Medicine and Herbal Products Drives Market Growth

           5.2      CHALLENGES

                         5.2.1      High Costs Associated with Early Toxicity Testing Hinders Market Growth

           5.3      OPPORTUNITIES

                         5.3.1      Integration of Advanced In-Vitro Testing Methods is Expected to Create Ample Growth Opportunity                       

6       INDONESIA EARLY TOXICITY TESTING MARKET BY TECHNIQUE

           6.1      OVERVIEW

           6.2      IN VIVO MARKET

           6.3      IN VITRO MARKET

                         6.3.1      Cell Culture

                         6.3.2      PCR

                         6.3.3      ELISA

                         6.3.4      Western Blotting

                         6.3.5      Protein Binding Assays

           6.4      IN SILICO MARKET

7       INDONESIA EARLY TOXICITY TESTING MARKET BY TOXICITY ENDPOINT

           7.1      OVERVIEW

           7.2      GENOTOXICITY MARKET

           7.3      DERMAL TOXICITY MARKET

           7.4      SKIN TOXICITY MARKET

           7.5      OCULAR TOXICITY MARKET

           7.6      PHOTOTOXICITY MARKET

           7.7      OTHERS MARKET

8       INDONESIA EARLY TOXICITY TESTING MARKET BY END USER

           8.1      OVERVIEW

           8.2      PHARMACEUTICAL INDUSTRY MARKET

           8.3      COSMETIC INDUSTRY MARKET

           8.4      CHEMICAL INDUSTRY MARKET

           8.5      FOOD INDUSTRY MARKET

           8.6      OTHERS MARKET

9     COMPANY PROFILES

           9.1     MSD

                         9.1.1     COMPANY OVERVIEW

                         9.1.2     COMPANY SNAPSHOT

                         9.1.3     OPERATING BUSINESS SEGMENTS

                         9.1.4     PRODUCT PORTFOLIO

                         9.1.5     BUSINESS PERFORMANCE

                         9.1.6     BUSINESS SEGMENTS

                         9.1.7     GEOGRAPHIC SEGMENTS

                         9.1.8     KEY STRATEGIC MOVES AND DEVELOPMENT

                         9.1.9     PRIMARY MARKET COMPETITORS

           9.2     DAEWOONG PHARMACEUTICAL COMPANY INDONESIA

                         9.2.1     COMPANY OVERVIEW

                         9.2.2     COMPANY SNAPSHOT

                         9.2.3     OPERATING BUSINESS SEGMENTS

                         9.2.4     PRODUCT PORTFOLIO

                         9.2.5     BUSINESS PERFORMANCE

                         9.2.6     BUSINESS SEGMENTS

                         9.2.7     GEOGRAPHIC SEGMENTS

                         9.2.8     KEY STRATEGIC MOVES AND DEVELOPMENT

                         9.2.9     PRIMARY MARKET COMPETITORS

           9.3     GSK INDONESIA

                         9.3.1     COMPANY OVERVIEW

                         9.3.2     COMPANY SNAPSHOT

                         9.3.3     OPERATING BUSINESS SEGMENTS

                         9.3.4     PRODUCT PORTFOLIO

                         9.3.5     BUSINESS PERFORMANCE

                         9.3.6     BUSINESS SEGMENTS

                         9.3.7     GEOGRAPHIC SEGMENTS

                         9.3.8     KEY STRATEGIC MOVES AND DEVELOPMENT

                         9.3.9     PRIMARY MARKET COMPETITORS

           9.4     KALBE FARMA

                         9.4.1     COMPANY OVERVIEW

                         9.4.2     COMPANY SNAPSHOT

                         9.4.3     OPERATING BUSINESS SEGMENTS

                         9.4.4     PRODUCT PORTFOLIO

                         9.4.5     BUSINESS PERFORMANCE

                         9.4.6     BUSINESS SEGMENTS

                         9.4.7     GEOGRAPHIC SEGMENTS

                         9.4.8     KEY STRATEGIC MOVES AND DEVELOPMENT

                         9.4.9     PRIMARY MARKET COMPETITORS

           9.5     EUROFINS SCIENTIFIC

                         9.5.1     COMPANY OVERVIEW

                         9.5.2     COMPANY SNAPSHOT

                         9.5.3     OPERATING BUSINESS SEGMENTS

                         9.5.4     PRODUCT PORTFOLIO

                         9.5.5     BUSINESS PERFORMANCE

                         9.5.6     BUSINESS SEGMENTS

                         9.5.7     GEOGRAPHIC SEGMENTS

                         9.5.8     KEY STRATEGIC MOVES AND DEVELOPMENT

                         9.5.9     PRIMARY MARKET COMPETITORS

           9.6     DEXA GROUP

                         9.6.1     COMPANY OVERVIEW

                         9.6.2     COMPANY SNAPSHOT

                         9.6.3     OPERATING BUSINESS SEGMENTS

                         9.6.4     PRODUCT PORTFOLIO

                         9.6.5     BUSINESS PERFORMANCE

                         9.6.6     BUSINESS SEGMENTS

                         9.6.7     GEOGRAPHIC SEGMENTS

                         9.6.8     KEY STRATEGIC MOVES AND DEVELOPMENT

                         9.6.9     PRIMARY MARKET COMPETITORS

           9.7     DDREG PHARMA

                         9.7.1     COMPANY OVERVIEW

                         9.7.2     COMPANY SNAPSHOT

                         9.7.3     OPERATING BUSINESS SEGMENTS

                         9.7.4     PRODUCT PORTFOLIO

                         9.7.5     BUSINESS PERFORMANCE

                         9.7.6     BUSINESS SEGMENTS

                         9.7.7     GEOGRAPHIC SEGMENTS

                         9.7.8     KEY STRATEGIC MOVES AND DEVELOPMENT

                         9.7.9     PRIMARY MARKET COMPETITORS

           9.8     SGS SA

                         9.8.1     COMPANY OVERVIEW

                         9.8.2     COMPANY SNAPSHOT

                         9.8.3     OPERATING BUSINESS SEGMENTS

                         9.8.4     PRODUCT PORTFOLIO

                         9.8.5     BUSINESS PERFORMANCE

                         9.8.6     BUSINESS SEGMENTS

                         9.8.7     GEOGRAPHIC SEGMENTS

                         9.8.8     KEY STRATEGIC MOVES AND DEVELOPMENT

                         9.8.9     PRIMARY MARKET COMPETITORS

           9.9     QPS HOLDINGS

                         9.9.1     COMPANY OVERVIEW

                         9.9.2     COMPANY SNAPSHOT

                         9.9.3     OPERATING BUSINESS SEGMENTS

                         9.9.4     PRODUCT PORTFOLIO

                         9.9.5     BUSINESS PERFORMANCE

                         9.9.6     BUSINESS SEGMENTS

                         9.9.7     GEOGRAPHIC SEGMENTS

                         9.9.8     KEY STRATEGIC MOVES AND DEVELOPMENT

                         9.9.9     PRIMARY MARKET COMPETITORS

           9.10     IMQUEST BIOSCIENCES

                         9.10.1     COMPANY OVERVIEW

                         9.10.2     COMPANY SNAPSHOT

                         9.10.3     OPERATING BUSINESS SEGMENTS

                         9.10.4     PRODUCT PORTFOLIO

                         9.10.5     BUSINESS PERFORMANCE

                         9.10.6     BUSINESS SEGMENTS

                         9.10.7     GEOGRAPHIC SEGMENTS

                         9.10.8     KEY STRATEGIC MOVES AND DEVELOPMENT

                         9.10.9     PRIMARY MARKET COMPETITORS

           9.11     LONZA

                         9.11.1     COMPANY OVERVIEW

                         9.11.2     COMPANY SNAPSHOT

                         9.11.3     OPERATING BUSINESS SEGMENTS

                         9.11.4     PRODUCT PORTFOLIO

                         9.11.5     BUSINESS PERFORMANCE

                         9.11.6     BUSINESS SEGMENTS

                         9.11.7     GEOGRAPHIC SEGMENTS

                         9.11.8     KEY STRATEGIC MOVES AND DEVELOPMENT

                         9.11.9     PRIMARY MARKET COMPETITORS

           9.12     INNOQUEST INDONESIA

                         9.12.1     COMPANY OVERVIEW

                         9.12.2     COMPANY SNAPSHOT

                         9.12.3     OPERATING BUSINESS SEGMENTS

                         9.12.4     PRODUCT PORTFOLIO

                         9.12.5     BUSINESS PERFORMANCE

                         9.12.6     BUSINESS SEGMENTS

                         9.12.7     GEOGRAPHIC SEGMENTS

                         9.12.8     KEY STRATEGIC MOVES AND DEVELOPMENT

                         9.12.9     PRIMARY MARKET COMPETITORS

           9.13     PPD LABORATORY SERVICES

                         9.13.1     COMPANY OVERVIEW

                         9.13.2     COMPANY SNAPSHOT

                         9.13.3     OPERATING BUSINESS SEGMENTS

                         9.13.4     PRODUCT PORTFOLIO

                         9.13.5     BUSINESS PERFORMANCE

                         9.13.6     BUSINESS SEGMENTS

                         9.13.7     GEOGRAPHIC SEGMENTS

                         9.13.8     KEY STRATEGIC MOVES AND DEVELOPMENT

                         9.13.9     PRIMARY MARKET COMPETITORS

           9.14     NAMSA

                         9.14.1     COMPANY OVERVIEW

                         9.14.2     COMPANY SNAPSHOT

                         9.14.3     OPERATING BUSINESS SEGMENTS

                         9.14.4     PRODUCT PORTFOLIO

                         9.14.5     BUSINESS PERFORMANCE

                         9.14.6     BUSINESS SEGMENTS

                         9.14.7     GEOGRAPHIC SEGMENTS

                         9.14.8     KEY STRATEGIC MOVES AND DEVELOPMENT

                         9.14.9     PRIMARY MARKET COMPETITORS

           9.15     EVIASEARCH

                         9.15.1     COMPANY OVERVIEW

                         9.15.2     COMPANY SNAPSHOT

                         9.15.3     OPERATING BUSINESS SEGMENTS

                         9.15.4     PRODUCT PORTFOLIO

                         9.15.5     BUSINESS PERFORMANCE

                         9.15.6     BUSINESS SEGMENTS

                         9.15.7     GEOGRAPHIC SEGMENTS

                         9.15.8     KEY STRATEGIC MOVES AND DEVELOPMENT

                         9.15.9     PRIMARY MARKET COMPETITORS

LIST OF TABLES

TABLE 1. INDONESIA EARLY TOXICITY TESTING MARKET VALUE, BY TECHNIQUE, 2022-2030, (MILLION USD)

TABLE 2. IN VIVO, MARKET VALUE, 2022-2030, (MILLION USD)

TABLE 3. IN VITRO, MARKET VALUE, 2022-2030, (MILLION USD)

TABLE 4. CELL CULTURE, MARKET VALUE, 2022-2030, (MILLION USD)

TABLE 5. PCR, MARKET VALUE, 2022-2030, (MILLION USD)

TABLE 6. ELISA, MARKET VALUE, 2022-2030, (MILLION USD)

TABLE 7. WESTERN BLOTTING, MARKET VALUE, 2022-2030, (MILLION USD)

TABLE 8. PROTEIN BINDING ASSAYS, MARKET VALUE, 2022-2030, (MILLION USD)

TABLE 9. IN SILICO, MARKET VALUE, 2022-2030, (MILLION USD)

TABLE 10. INDONESIA EARLY TOXICITY TESTING MARKET VALUE, BY TOXICITY ENDPOINT, 2022-2030, (MILLION USD)

TABLE 11. GENOTOXICITY, MARKET VALUE, 2022-2030, (MILLION USD)

TABLE 12. DERMAL TOXICITY, MARKET VALUE, 2022-2030, (MILLION USD)

TABLE 13. SKIN TOXICITY, MARKET VALUE, 2022-2030, (MILLION USD)

TABLE 14. OCULAR TOXICITY, MARKET VALUE, 2022-2030, (MILLION USD)

TABLE 15. PHOTOTOXICITY, MARKET VALUE, 2022-2030, (MILLION USD)

TABLE 16. OTHERS, MARKET VALUE, 2022-2030, (MILLION USD)

TABLE 17. INDONESIA EARLY TOXICITY TESTING MARKET VALUE, BY END USER, 2022-2030, (MILLION USD)

TABLE 18. PHARMACEUTICAL INDUSTRY, MARKET VALUE, 2022-2030, (MILLION USD)

TABLE 19. COSMETIC INDUSTRY, MARKET VALUE, 2022-2030, (MILLION USD)

TABLE 20. CHEMICAL INDUSTRY, MARKET VALUE, 2022-2030, (MILLION USD)

TABLE 21. FOOD INDUSTRY, MARKET VALUE, 2022-2030, (MILLION USD)

TABLE 22. OTHERS, MARKET VALUE, 2022-2030, (MILLION USD)

TABLE 23. MSD: COMPANY SNAPSHOT

TABLE 24. MSD: OPERATING BUSINESS SEGMENTS

TABLE 25. MSD: PRODUCT PORTFOLIO

TABLE 26. MSD: SALES BY BUSINESS SEGMENTS (2020-2022)

TABLE 27. MSD: SALES BY GEOGRAPHIC SEGMENTS (2020-2022)

TABLE 28. MSD: KEY STRATERGY

TABLE 29. DAEWOONG PHARMACEUTICAL COMPANY INDONESIA: COMPANY SNAPSHOT

TABLE 30. DAEWOONG PHARMACEUTICAL COMPANY INDONESIA: OPERATING BUSINESS SEGMENTS

TABLE 31. DAEWOONG PHARMACEUTICAL COMPANY INDONESIA: PRODUCT PORTFOLIO

TABLE 32. DAEWOONG PHARMACEUTICAL COMPANY INDONESIA: SALES BY BUSINESS SEGMENTS (2020-2022)

TABLE 33. DAEWOONG PHARMACEUTICAL COMPANY INDONESIA: SALES BY GEOGRAPHIC SEGMENTS (2020-2022)

TABLE 34. DAEWOONG PHARMACEUTICAL COMPANY INDONESIA: KEY STRATERGY

TABLE 35. GSK INDONESIA: COMPANY SNAPSHOT

TABLE 36. GSK INDONESIA: OPERATING BUSINESS SEGMENTS

TABLE 37. GSK INDONESIA: PRODUCT PORTFOLIO

TABLE 38. GSK INDONESIA: SALES BY BUSINESS SEGMENTS (2020-2022)

TABLE 39. GSK INDONESIA: SALES BY GEOGRAPHIC SEGMENTS (2020-2022)

TABLE 40. GSK INDONESIA: KEY STRATERGY

TABLE 41. KALBE FARMA: COMPANY SNAPSHOT

TABLE 42. KALBE FARMA: OPERATING BUSINESS SEGMENTS

TABLE 43. KALBE FARMA: PRODUCT PORTFOLIO

TABLE 44. KALBE FARMA: SALES BY BUSINESS SEGMENTS (2020-2022)

TABLE 45. KALBE FARMA: SALES BY GEOGRAPHIC SEGMENTS (2020-2022)

TABLE 46. KALBE FARMA: KEY STRATERGY

TABLE 47. EUROFINS SCIENTIFIC: COMPANY SNAPSHOT

TABLE 48. EUROFINS SCIENTIFIC: OPERATING BUSINESS SEGMENTS

TABLE 49. EUROFINS SCIENTIFIC: PRODUCT PORTFOLIO

TABLE 50. EUROFINS SCIENTIFIC: SALES BY BUSINESS SEGMENTS (2020-2022)

TABLE 51. EUROFINS SCIENTIFIC: SALES BY GEOGRAPHIC SEGMENTS (2020-2022)

TABLE 52. EUROFINS SCIENTIFIC: KEY STRATERGY

TABLE 53. DEXA GROUP: COMPANY SNAPSHOT

TABLE 54. DEXA GROUP: OPERATING BUSINESS SEGMENTS

TABLE 55. DEXA GROUP: PRODUCT PORTFOLIO

TABLE 56. DEXA GROUP: SALES BY BUSINESS SEGMENTS (2020-2022)

TABLE 57. DEXA GROUP: SALES BY GEOGRAPHIC SEGMENTS (2020-2022)

TABLE 58. DEXA GROUP: KEY STRATERGY

TABLE 59. DDREG PHARMA: COMPANY SNAPSHOT

TABLE 60. DDREG PHARMA: OPERATING BUSINESS SEGMENTS

TABLE 61. DDREG PHARMA: PRODUCT PORTFOLIO

TABLE 62. DDREG PHARMA: SALES BY BUSINESS SEGMENTS (2020-2022)

TABLE 63. DDREG PHARMA: SALES BY GEOGRAPHIC SEGMENTS (2020-2022)

TABLE 64. DDREG PHARMA: KEY STRATERGY

TABLE 65. SGS SA: COMPANY SNAPSHOT

TABLE 66. SGS SA: OPERATING BUSINESS SEGMENTS

TABLE 67. SGS SA: PRODUCT PORTFOLIO

TABLE 68. SGS SA: SALES BY BUSINESS SEGMENTS (2020-2022)

TABLE 69. SGS SA: SALES BY GEOGRAPHIC SEGMENTS (2020-2022)

TABLE 70. SGS SA: KEY STRATERGY

TABLE 71. QPS HOLDINGS: COMPANY SNAPSHOT

TABLE 72. QPS HOLDINGS: OPERATING BUSINESS SEGMENTS

TABLE 73. QPS HOLDINGS: PRODUCT PORTFOLIO

TABLE 74. QPS HOLDINGS: SALES BY BUSINESS SEGMENTS (2020-2022)

TABLE 75. QPS HOLDINGS: SALES BY GEOGRAPHIC SEGMENTS (2020-2022)

TABLE 76. QPS HOLDINGS: KEY STRATERGY

TABLE 77. IMQUEST BIOSCIENCES: COMPANY SNAPSHOT

TABLE 78. IMQUEST BIOSCIENCES: OPERATING BUSINESS SEGMENTS

TABLE 79. IMQUEST BIOSCIENCES: PRODUCT PORTFOLIO

TABLE 80. IMQUEST BIOSCIENCES: SALES BY BUSINESS SEGMENTS (2020-2022)

TABLE 81. IMQUEST BIOSCIENCES: SALES BY GEOGRAPHIC SEGMENTS (2020-2022)

TABLE 82. IMQUEST BIOSCIENCES: KEY STRATERGY

TABLE 83. LONZA: COMPANY SNAPSHOT

TABLE 84. LONZA: OPERATING BUSINESS SEGMENTS

TABLE 85. LONZA: PRODUCT PORTFOLIO

TABLE 86. LONZA: SALES BY BUSINESS SEGMENTS (2020-2022)

TABLE 87. LONZA: SALES BY GEOGRAPHIC SEGMENTS (2020-2022)

TABLE 88. LONZA: KEY STRATERGY

TABLE 89. INNOQUEST INDONESIA: COMPANY SNAPSHOT

TABLE 90. INNOQUEST INDONESIA: OPERATING BUSINESS SEGMENTS

TABLE 91. INNOQUEST INDONESIA: PRODUCT PORTFOLIO

TABLE 92. INNOQUEST INDONESIA: SALES BY BUSINESS SEGMENTS (2020-2022)

TABLE 93. INNOQUEST INDONESIA: SALES BY GEOGRAPHIC SEGMENTS (2020-2022)

TABLE 94. INNOQUEST INDONESIA: KEY STRATERGY

TABLE 95. PPD LABORATORY SERVICES: COMPANY SNAPSHOT

TABLE 96. PPD LABORATORY SERVICES: OPERATING BUSINESS SEGMENTS

TABLE 97. PPD LABORATORY SERVICES: PRODUCT PORTFOLIO

TABLE 98. PPD LABORATORY SERVICES: SALES BY BUSINESS SEGMENTS (2020-2022)

TABLE 99. PPD LABORATORY SERVICES: SALES BY GEOGRAPHIC SEGMENTS (2020-2022)

TABLE 100. PPD LABORATORY SERVICES: KEY STRATERGY

TABLE 101. NAMSA: COMPANY SNAPSHOT

TABLE 102. NAMSA: OPERATING BUSINESS SEGMENTS

TABLE 103. NAMSA: PRODUCT PORTFOLIO

TABLE 104. NAMSA: SALES BY BUSINESS SEGMENTS (2020-2022)

TABLE 105. NAMSA: SALES BY GEOGRAPHIC SEGMENTS (2020-2022)

TABLE 106. NAMSA: KEY STRATERGY

TABLE 107. EVIASEARCH: COMPANY SNAPSHOT

TABLE 108. EVIASEARCH: OPERATING BUSINESS SEGMENTS

TABLE 109. EVIASEARCH: PRODUCT PORTFOLIO

TABLE 110. EVIASEARCH: SALES BY BUSINESS SEGMENTS (2020-2022)

TABLE 111. EVIASEARCH: SALES BY GEOGRAPHIC SEGMENTS (2020-2022)

TABLE 112. EVIASEARCH: KEY STRATERGY

LIST OF FIGURES

FIGURE 1. BARGAINING POWER OF SUPPLIERS

FIGURE 2. BARGAINING POWER OF BUYERS

FIGURE 3. DEGREE OF COMPETITION

FIGURE 4. THREAT OF SUBSTITUTE

FIGURE 5. THREAT OF NEW ENTRANTS

FIGURE 6. INDONESIA EARLY TOXICITY TESTING MARKET VALUE, BY TECHNIQUE, 2022-2030, (MILLION USD)

FIGURE 7. IN VIVO, MARKET VALUE, 2022-2030, (MILLION USD)

FIGURE 8. IN VITRO, MARKET VALUE, 2022-2030, (MILLION USD)

FIGURE 9. CELL CULTURE, MARKET VALUE, 2022-2030, (MILLION USD)

FIGURE 10. PCR, MARKET VALUE, 2022-2030, (MILLION USD)

FIGURE 11. ELISA, MARKET VALUE, 2022-2030, (MILLION USD)

FIGURE 12. WESTERN BLOTTING, MARKET VALUE, 2022-2030, (MILLION USD)

FIGURE 13. PROTEIN BINDING ASSAYS, MARKET VALUE, 2022-2030, (MILLION USD)

FIGURE 14. IN SILICO, MARKET VALUE, 2022-2030, (MILLION USD)

FIGURE 15. INDONESIA EARLY TOXICITY TESTING MARKET VALUE, BY TOXICITY ENDPOINT, 2022-2030, (MILLION USD)

FIGURE 16. GENOTOXICITY, MARKET VALUE, 2022-2030, (MILLION USD)

FIGURE 17. DERMAL TOXICITY, MARKET VALUE, 2022-2030, (MILLION USD)

FIGURE 18. SKIN TOXICITY, MARKET VALUE, 2022-2030, (MILLION USD)

FIGURE 19. OCULAR TOXICITY, MARKET VALUE, 2022-2030, (MILLION USD)

FIGURE 20. PHOTOTOXICITY, MARKET VALUE, 2022-2030, (MILLION USD)

FIGURE 21. OTHERS, MARKET VALUE, 2022-2030, (MILLION USD)

FIGURE 22. INDONESIA EARLY TOXICITY TESTING MARKET VALUE, BY END USER, 2022-2030, (MILLION USD)

FIGURE 23. PHARMACEUTICAL INDUSTRY, MARKET VALUE, 2022-2030, (MILLION USD)

FIGURE 24. COSMETIC INDUSTRY, MARKET VALUE, 2022-2030, (MILLION USD)

FIGURE 25. CHEMICAL INDUSTRY, MARKET VALUE, 2022-2030, (MILLION USD)

FIGURE 26. FOOD INDUSTRY, MARKET VALUE, 2022-2030, (MILLION USD)

FIGURE 27. OTHERS, MARKET VALUE, 2022-2030, (MILLION USD)

FIGURE 28. MSD: NET SALES, (2020-2022)

FIGURE 29. MSD: PRIMARY MARKET COMPETITORS

FIGURE 30. DAEWOONG PHARMACEUTICAL COMPANY INDONESIA: NET SALES, (2020-2022)

FIGURE 31. DAEWOONG PHARMACEUTICAL COMPANY INDONESIA: PRIMARY MARKET COMPETITORS

FIGURE 32. GSK INDONESIA: NET SALES, (2020-2022)

FIGURE 33. GSK INDONESIA: PRIMARY MARKET COMPETITORS

FIGURE 34. KALBE FARMA: NET SALES, (2020-2022)

FIGURE 35. KALBE FARMA: PRIMARY MARKET COMPETITORS

FIGURE 36. EUROFINS SCIENTIFIC: NET SALES, (2020-2022)

FIGURE 37. EUROFINS SCIENTIFIC: PRIMARY MARKET COMPETITORS

FIGURE 38. DEXA GROUP: NET SALES, (2020-2022)

FIGURE 39. DEXA GROUP: PRIMARY MARKET COMPETITORS

FIGURE 40. DDREG PHARMA: NET SALES, (2020-2022)

FIGURE 41. DDREG PHARMA: PRIMARY MARKET COMPETITORS

FIGURE 42. SGS SA: NET SALES, (2020-2022)

FIGURE 43. SGS SA: PRIMARY MARKET COMPETITORS

FIGURE 44. QPS HOLDINGS: NET SALES, (2020-2022)

FIGURE 45. QPS HOLDINGS: PRIMARY MARKET COMPETITORS

FIGURE 46. IMQUEST BIOSCIENCES: NET SALES, (2020-2022)

FIGURE 47. IMQUEST BIOSCIENCES: PRIMARY MARKET COMPETITORS

FIGURE 48. LONZA: NET SALES, (2020-2022)

FIGURE 49. LONZA: PRIMARY MARKET COMPETITORS

FIGURE 50. INNOQUEST INDONESIA: NET SALES, (2020-2022)

FIGURE 51. INNOQUEST INDONESIA: PRIMARY MARKET COMPETITORS

FIGURE 52. PPD LABORATORY SERVICES: NET SALES, (2020-2022)

FIGURE 53. PPD LABORATORY SERVICES: PRIMARY MARKET COMPETITORS

FIGURE 54. NAMSA: NET SALES, (2020-2022)

FIGURE 55. NAMSA: PRIMARY MARKET COMPETITORS

FIGURE 56. EVIASEARCH: NET SALES, (2020-2022)

FIGURE 57. EVIASEARCH: PRIMARY MARKET COMPETITORS

 

At Next Move Strategy Consulting, we understand that insightful market research is the cornerstone of successful business decisions. That's why we employ a robust and multifaceted approach, combining various methodologies to deliver the most accurate and actionable data for our clients.

Research Landscape

We navigate the world of research with two primary approaches:

Qualitative Approach

Our qualitative research methodologies involve immersive techniques such as in-depth interviews, focus groups, and observational studies. By engaging directly with individuals and stakeholders, we uncover valuable insights that quantitative data alone may overlook.

Quantitative Research

In tandem with qualitative methodologies, NMSC leverages the power of Quantitative Research to provide a robust foundation of numerical insights. Through systematic data collection and analysis, we quantify patterns, preferences, and market trends, offering a comprehensive view of the business landscape.

Our quantitative research approach employs diverse tools, including surveys, experiments, and statistical modelling. These methodologies enable us to gather data from a large and representative sample, ensuring the statistical significance of our findings. By employing structured questionnaires and standardized data collection methods, we guarantee the reliability and validity of the information we present to our clients.

Quantitative research is particularly effective in measuring the prevalence of trends, assessing market size, and gauging the impact of various factors on consumer behavior. The numerical precision attained through this approach equips our clients with actionable insights, facilitating data-driven decision-making and strategy formulation.

 

Our Specialized Toolbox for Industry-Specific Market Research

We deploy a specialized arsenal of techniques tailored to meet your unique requirements. Here's a glimpse into our comprehensive toolbox:

Information Procurement

The stage entails acquiring market data or relevant information through various sources and methodologies.

Market Research Approach

We utilize both top-down and bottom-up approaches in market research analysis to achieve a comprehensive understanding of the market dynamics, leveraging the broad perspective of industry trends and macroeconomic factors alongside detailed insights from specific segments and individual companies.

Porters Five Forces Analysis

We conduct Porter's Five Forces analysis to evaluate the competitive landscape of an industry, providing us with insights into factors that affect profitability and strategic positioning.

              

SWOT Analysis

We conduct SWOT analysis to understand market trends, identify potential threats, capitalize on opportunities, and assess our strengths and weaknesses.

Forecasting

We utilize a forecasting model to predict future consumption by considering parameters like population, economics, regulations, market competition, drivers, constraints, technology, and pricing. We also employ statistical techniques such as multilinear regression, exponential smoothing, moving average, ARIMA, and Monte Carlo simulations for accurate predictions. In econometric forecasting, we analyzed short-term and long-term event impacts, attributing values based on regulatory frameworks, economic factors, and market events.